Adverse events: hypotension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse effects of antibiotics (skin rash) · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: skin rash compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: mild dyspnoea · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: mild dyspnoea compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in scores indicating clinical improvement) at 1‐month (with actual · people with dry eye
1 finding from 1 review
Ocular surface staining · people with dry eye
1 finding from 1 review
Aqueous tear production · people with dry eye
1 finding from 1 review
Tear film stability · people with dry eye
1 finding from 1 review
Frequency of artificial tear usage at 6 months · people with dry eye
1 finding from 1 review
Conjunctival goblet cell density (cells per unit) at 6 months · people with dry eye
1 finding from 1 review
Treatment related adverse events, · people with dry eye
1 finding from 1 review
Clinical relapse · SSNS in children
Cyclosporin plus prednisolone may leads to lower relapse at 6 months compared with prednisolone alone (low certainty).
1 finding from 1 review
Relapse · SSNS in children
Cyclosporin plus prednisolone showed no clear difference in relapse at 12 months compared with prednisolone alone (low certainty).
1 finding from 1 review
Frequent relapses · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: number needing cytotoxic agents · SSNS in children
It is very uncertain whether cyclosporin plus prednisolone changes adverse effects: number needing cytotoxic agents compared with prednisolone alone (very low certainty).
1 finding from 1 review
Adverse effects: creatinine at the end of study · SSNS in children
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Safety of the intervention (adverse effects) · People with Behcet's disease with a history of recurrent oral aphthous-type (RAS-type) ulcers diagnosed clinically; primary care
1 finding from 1 review
Primary: investigator‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: investigator‐ rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review
Primary: participant‐rated good/excellent control of symptoms · people with hand eczema, continuously for 6 months, significant disability, inadequate response to conventional treatment, confirmation by…
Oral immunosuppressants: oral cyclosporin showed no clear difference in primary: participant‐rated good/excellent control of symptomsb compared with topical betamethasone dipropionate (moderate certainty).
1 finding from 1 review